FDA Expands Cystic Fibrosis Treatment Approval to Children Ages 6 to 12

Symdeko previously approved for patients ≥ 12 years with cystic fibrosis and certain genetic mutations
Source: Pulmonary Medicine News - Doctors Lounge - Category: Respiratory Medicine Tags: Pediatrics, Pharmacy, Pulmonology, Institutional, Source Type: news